Initiate Phase 2 dose selection for CAEL-101
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 30 Jan 2020
- Due
- 30 Jun 2020
- Delivered
- Q1 2020
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Phase 2 dose selection portion of the program will initiate in the first half of 2020”
What we found
Evidence strength A What the grades mean
The company initiated the Phase 2 trial for CAEL-101 in the first quarter of 2020, which confirmed the dose and regimen for subsequent Phase 3 studies.
-
A Alexion Pharmaceuticals 10-Q filed 2020-07-30
“a Phase II trial for CAEL-101 commenced during the first quarter of 2020” ✓ confirmed on the page
-
A Alexion Pharmaceuticals 10-Q filed 2020-10-29
“A Phase II trial for CAEL-101 subsequently commenced during the first quarter of 2020 and met its primary objectives, supporting the safety and tolerability of CAEL-101 and confirmed the dose and regimen to be adopted for the Phase III studies.” ✓ confirmed on the page
Checked 21 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Initiate
- Deliverable
- Phase 2 dose selection for CAEL-101
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Alexion Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2020-C899866-019370 · Corrections policy